RecruitingPhase 2NCT07227779

B-PaLMZ for TB Meningitis

A PHASE 2 NOVEL ANTIMICROBIAL COMBINATION THERAPY TO TREAT TUBERCULOUS MENINGITIS

Sponsor

David Boulware

Enrollment

240 participants

Start Date

Jul 28, 2026

Study Type

INTERVENTIONAL

Conditions

HIV Meningitis Tuberculous Meningitis TB - Tuberculosis

Summary

This two-stage study will compare consented research participants with tuberculous meningitis receiving BPaLMZ to controls receiving SOC of rifampicin (R), isoniazid (H), pyrazinamide (Z), and ethambutol (E), known as RHZE.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called BPaLMZ Regimen for people with hiv, meningitis, and other related conditions. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.